INS and type 2 diabetes mellitus: GLP‐1 users had less peri‐implant bone loss vs insulin/metformin at 1 year [142]; exenatide enhances osseointegration in T2DM rats [143]; local exendin‐4 microspheres improve bone formation independent of glycemia [144].